Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
92.08
+3.69 (4.17%)
At close: Feb 27, 2026, 4:00 PM EST
92.09
+0.01 (0.01%)
After-hours: Feb 27, 2026, 5:48 PM EST
Protagonist Therapeutics Revenue
In the year 2025, Protagonist Therapeutics had annual revenue of $46.02M, down -89.41%. Protagonist Therapeutics had revenue of $7.44M in the quarter ending December 31, 2025, a decrease of -95.64%.
Revenue (ttm)
$46.02M
Revenue Growth
-89.41%
P/S Ratio
127.68
Revenue / Employee
$359,500
Employees
128
Market Cap
5.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.02M | -388.42M | -89.41% |
| Dec 31, 2024 | 434.43M | 374.43M | 624.06% |
| Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
| Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
| Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
| Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
| Dec 31, 2019 | 231.00K | -30.69M | -99.25% |
| Dec 31, 2018 | 30.93M | 10.86M | 54.14% |
| Dec 31, 2017 | 20.06M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 649.06M |
| Mirum Pharmaceuticals | 521.31M |
| Rhythm Pharmaceuticals | 189.76M |
| CRISPR Therapeutics AG | 3.51M |
| CG Oncology | 2.17M |
PTGX News
- 2 days ago - CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Accesswire
- 2 days ago - Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Accesswire
- 3 days ago - Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 - Accesswire
- 6 weeks ago - Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - Accesswire
- 7 weeks ago - Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) - Business Wire
- 2 months ago - Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - Business Wire
- 4 months ago - Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Accesswire